| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2018-08-16 |
BioNTech (Germany) Pfizer (USA - NY) |
mRNA?based flu vaccines |
influenza (flu) |
research - development - R&D |
Infectious diseases |
Development agreement |
| 2018-08-07 |
Infinity Pharmaceuticals (USA - MA) |
|
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-08-06 |
Boehringer Ingelheim (Germany) Oxford Biomedica (UK) UK Cystic Fibrosis Gene Therapy Consortium (UK) Imperial Innovations (UK) |
replication-deficient lentiviral vector in an inhaled formulation, to introduce a healthy copy of the CFTR gene into the cells of the lung |
cystic fibrosis |
collaboration |
Rare diseases - Genetic diseases - Respiratory diseases |
Collaboration agreement |
| 2018-08-06 |
Bluebird bio (USA - MA) Regeneron Pharmaceuticals (USA - NY) |
immune cell therapies |
|
research - development - R&D - commercialisation |
Cancer - Oncology |
Collaboration agreement |
| 2018-08-03 |
HTG Molecular Diagnostics (USA - AZ) Oncologie (USA - MA) |
biomarkers associated with Oncologie’s Immuno-oncology pipeline |
|
development |
|
Development agreement |
| 2018-08-02 |
Atlantic Healthcare (UK) |
US president and CEO |
|
nomination |
Inflammatory diseases - Gastrointestinal diseases |
Nomination |
| 2018-08-02 |
Orchard Therapeutics (UK) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-08-01 |
BioNTech (Germany) SiO2 Medical Products (“SMP”) (USA - Ala) |
packaging and application devices for mRNA therapeutics |
|
collaboration |
Technology - Services |
Collaboration agreement |
| 2018-07-25 |
GSK (UK) 23andme (USA - CA) |
|
|
collaboration - research - development |
|
Collaboration agreement |
| 2018-07-10 |
MedImmune (USA - global biologics arm of AstraZeneca (UK) 4D Molecular Therapeutics (USA - CA) |
AAV vectors |
chronic lung disease |
development - commercialisation |
Lung diseases - Respiratory diseases |
Development agreement |
| 2018-07-10 |
BioNTech (Germany) Genevant Sciences (USA - MA) |
five mRNA therapeutic programs for rare diseases with high unmet
medical need |
Rare diseases |
development - commercialisation |
Rare diseases - Genetic diseases |
Development agreement |
| 2018-07-09 |
Orchard Therapeutics (UK) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-07-09 |
Benitec Biopharma (Australia) Axovant (UK) |
- BB-301, now named AXO-AAV-OPMD (genetically modified adeno-associated viral vector serotype 9 expressing shRNA as well as a codon-optimised shRNA-insensitive wildtype PABPN1) and five additional gene therapy products in neurological disorders
|
oculopharyngeal muscular dystrophy (OPMD) amyotrophic lateral sclerosis (ALS) frontotemporal dementia (FTD) |
licensing - research - development |
Rare diseases - Genetic diseases - Neurological diseases |
Licensing agreement |
| 2018-06-29 |
Orchard Therapeutics (UK) |
chairman of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-06-27 |
Avrobio (USA - MA) |
member of the board of directors |
|
nomination |
Cancer - Oncology - Rare diseases - Genetic diseases - Lysosomal diseases |
Nomination |
| 2018-06-11 |
RegenXBio (USA - MD) Avexis (USA - MA) |
products to treat Spinal Muscular Atrophy (SMA) using NAV rAAV9 vectors |
spinal muscular atrophy |
licensing |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Milestone |
| 2018-06-08 |
Amicus Therapeutics (USA - NJ) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-06-07 |
Orchard Therapeutics (UK) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-05-29 |
BioNTech (Germany) |
|
|
nomination |
Cancer - Oncology - Infectious diseases |
Nomination |
| 2018-05-15 |
Horama (France) |
chairman of the board of directors |
|
nomination |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Nomination |
